Wiseguyreports.Com Publish New Report On -“TNF Inhibitors 2017 Global Market – Assessment, Insight, Trends, Key Players – Analysis to 2021”
PUNE, INDIA, October 30, 2017 /EINPresswire.com/ —
The TNF inhibitors pipeline analysis report includes ongoing clinical and non-clinical trends in the global TNF inhibitors market. The anti-TNF drugs are among the top 10 global blockbuster drugs and have dominated the global pharmaceutical market landscape for many years. The report includes classification of the pipeline by type of molecules such monoclonal antibody, polyclonal antibody, recombinant fusion protein, and a small molecule.
Around 45% of TNF inhibitors in pipeline are being evaluated for the treatment of RA. According to the Centers for Disease Control and Prevention (CDC), around 78 million (26%) US adults aged 18 years or older are projected to have doctor-diagnosed arthritis by 2040.
Covered in this report
The report covers the present scenario and the growth prospects of the TNF inhibitors. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
Request a Sample Report @ https://www.wiseguyreports.com/sample-request/2431341-tnf-inhibitors-a-pipeline-analysis-report
The TNF Inhibitors – A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period. The report also includes a discussion of the key companies operating in this market.
• Boehringer Ingelheim
• Mochida Pharmaceutical
Key questions answered in this report
• How will the market evolve during the forecast period?
• What are the major parameters impacting the market?
• What are the key market trends?
• What are the challenges to market growth?
• Who are the key companies in this market space?
Any Query, Submit Here @ https://www.wiseguyreports.com/enquiry/2431341-tnf-inhibitors-a-pipeline-analysis-report
Table of Contents –Analysis of Key Points
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: TNF INHIBITOR INSIGHT
PART 05: PIPELINE LANDSCAPE
PART 06: PIPELINE MOLECULES BY VENDORS
PART 07: COMPARATIVE ANALYSIS
• Late-stage molecules (filed and Phase III)
• Mid-stage molecules (Phase II)
• Early-stage molecules (Phase I and IND)
• Pre-clinical molecules
• Status unknown molecules
• Discontinued products
• Dormant products
PART 08: INDICATION ANALYSIS
PART 09: MARKETED DRUGS
• Top selling drugs
PART 10: THERAPEUTIC ASSESSMENT BY THERAPY
• Therapeutic assessment based on therapy
PART 11: THERAPEUTIC ASSESSMENT BY ROA
• Therapeutic assessment based on RoA
PART 12: THERAPEUTIC ASSESSMENT BY MOLECULE TYPE
• Therapeutic assessment based on molecule type
PART 13: KEY COMPANIES
• Active companies: Category and parameters
PART 14: APPENDIX
• List of abbreviations
+1 646 845 9349 / +44 208 133 9349